Physician profile
Ajith Ramachandran
NPI 1235125170
$16,799.20
in general payments reported to CMS, 2019-2025
65 companies · $2,044 in 2025
The $2,044 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,807 · 2020: $1,807 · 2021: $2,861 · 2022: $2,764 · 2023: $2,930 · 2024: $2,586 · 2025: $2,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,559.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,519.46 | 2019-2025 | |
| Amgen INC. | $2,447.70 | 2019-2025 | Otezla, Enbrel, Tavneos |
| Ucb, INC. | $1,778.85 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $1,193.37 | 2019-2025 | Benlysta, Nucala, Shingrix |
| Novartis Pharmaceuticals Corporation | $941.14 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $814.14 | 2019-2025 | Ofev, Jardiance, Synjardy |
| Mallinckrodt Hospital Products INC. | $787.90 | 2020-2025 | Acthar |
| Lilly USA, LLC | $593.86 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Janssen Biotech, INC. | $545.90 | 2020-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $382.91 | 2019-2021 | |
| Novo Nordisk INC | $377.83 | 2019-2025 | Wegovy |
| Mannkind Corporation | $352.43 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $349.64 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $317.34 | 2019-2023 | |
| Astellas Pharma US INC | $267.03 | 2019-2024 | Veozah |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajith Ramachandran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.